A Multinational Study to Measure the Value that Patients with Cancer Place on Improved Emesis Control Following Cisplatin Chemotherapy
| Autor: | Maria Spinthouri, Renoto Ciotti, Antonello Quadri, Roberto Labianca, Lycurgus Liaropoulos, Ana Ortega, George Dranitsaris, Pauline Leung |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
Oncology Canada medicine.medical_specialty Vomiting medicine.drug_class Nausea medicine.medical_treatment jel:D Antineoplastic Agents jel:C jel:I jel:I1 Neoplasms Internal medicine medicine Humans Antiemetic Dolasetron Pharmacology Cisplatin Chemotherapy jel:Z business.industry Antiemetics Nausea Neurokinin 1 antagonists Pharmacoeconomics Quality of life Vomiting Health Policy Public Health Environmental and Occupational Health Middle Aged jel:I11 Europe jel:I18 jel:I19 Anesthesia Income Quality of Life Antiemetics Female Tropisetron NK1 receptor antagonist medicine.symptom business Attitude to Health medicine.drug |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 1170-7690 |
| DOI: | 10.2165/00019053-200119090-00007 |
| Popis: | The neurokinin-1 (NK1) receptor antagonists are a new class of agents designed to reduce the risk of emesis following chemotherapy, particularly with cisplatin. Early data from double-blind randomised trials suggest that an orally administered NK1 antagonist can reduce the absolute risk of acute and delayed emesis following cisplatin by 20 and 30%, respectively.To measure the value that patients with cancer place on improved emesis control and quality of life.Willingness-to-pay analysis.Five study sites in Canada, Italy, Spain and Greece.245 patients with cancer either receiving chemotherapy with cisplatin or who had received cisplatin-based chemotherapy within the previous 6 months.After background information had been presented, patients were asked to define the maximum that they would pay per day for a drug that reduced their risk of acute and delayed (days 2 to 5) emesis by 20 and 30%, respectively. Costs were converted to US dollars ($US) using year 2000 exchange rates.For a 20% improvement in acute emesis, Canadian, Italian and Spanish patients with cancer were willing to pay $US46, $US34 and $US63 per day, respectively, compared with $US8 for patients from Greece (p0.001). For a 30% improvement in delayed emesis, Canadian, Italian and Spanish patients with cancer were also willing to pay more than their Greek counterparts (SUS41, $US31, $US50 and $US9 daily for 4 days, respectively; p0.001). These significant differences in patient value between countries remained, even after adjusting for socioeconomic variables and previous history of emesis.There are substantial cultural differences in how patients with cancer value benefit and improved quality of life. Since the majority of the world's population resides outside North America and Western Europe, there may be a need to re-evaluate perceived levels of patient benefit and measures of quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink